To build an integrated AI platform for early drug discovery and evaluation, Medicilon and DP Technology reached a strategic collaboration
Recently, Shanghai Medicilon Inc. (Medicilon) and DP Technology Ltd. announced the signing of a strategic collaboration agreement. The two parties will work together to build an integrated AI platform for early drug discovery and evaluation based on AI4S.
Medicilon: Build an AI-based one-stop preclinical R&D service platform
At present, the AI+CRO model is rapidly gaining popularity around the world and is accelerating the transformation of the biopharmaceutical industry. As a supporter of emerging technologies, Medicilon has been actively exploring the frontier technologies of drug development for 19 years. In the field of AI pharmaceuticals, on the basis of collaboration with a number of AI innovative drug R&D companies, Medicilon will use the druggability evaluation and prediction platform of virtual drugs, drug intelligent target database, drug-molecule database, drug binding model database, drug designed AI generation model and AI virtual drug screening system and other platform systems to improve the efficiency of screening and synthesis of candidate drugs, and strive to build a whole path to quickly realize AI drugs from beginning to IND approval.
DP Technology: Create a new generation of micro-scale industrial infrastructure (Industrial Infrastructure for Computational Design of Medicines)
As the leader and practitioner of the “AI for Science” scientific research paradigm, DP Technology is committed to using AI and molecular simulation algorithms, combined with advanced computing methods to solve important scientific problems, to create a new generation of micro-scale industrial design and simulation platform for the most basic biomedicine, energy, materials and information science and engineering research of human. In particular, DP Technology pioneered the new scientific research paradigm of “multi-scale modeling + machine learning + high-performance computing”, and launched the Bohrium® micro-scale scientific computing cloud platform, Hermite® drug computing design platform, RiDYMO™ Strengthen micro-scale industrial design infrastructure such as dynamics platform and battery material calculation design platform. All these subvert the existing research and development model and create a new paradigm of “computation-guided experiments and experimental optimization design”.
CRO+AI mutual benefit and symbiosis, advancing towards the era of smart medicine
One is a few one-stop biopharmaceutical preclinical R&D service platform in the scientific research field, and the other is an AI4S practitioner leading one of the new paradigms of the current scientific and technological revolution. Medicilon and DP Technology will create more possibilities for new drug research and development in the two-way empowerment. In this strategic collaboration, Medicilon will make full use of the rich project development experience of the drug discovery team, give full play to its excellent drug synthesis and design capabilities, and combine the AI4S computing design platform Hermite® of DP Technology to assist in the screening and optimization of compound activity, and use the Uni-Mol pre-training model to improve the prediction accuracy of the druggability model, enabling pharmacodynamics, pharmacokinetics, and toxicology safety evaluation research.
AI helps CRO to accelerate drug discovery, and CRO helps AI drugs to go to clinic faster. The cross-industry collaboration between Medicilon and DP Technology will further promote the mutual benefit and symbiosis of AI and CRO, and jointly catalyze the upgrading and expansion of drug R&D in terms of speed, difficulty and breadth.
Dr. Chunlin Chen, founder and CEO of Medicilon, and rotating chairman of Zhangjiang AI New Drug R&D Alliance said, “AI is leading the transformation of the drug R&D paradigm, and DP Technology is a leader in using AI and molecular simulation to empower drug R&D. It is believed that with the assist of DP Technology’s AI4S new paradigm and successful application experience, Medicilon’s drug discovery capabilities will be raised to a new level. This will further accelerate and empower Medicilon’s partners to use new technologies to discover and develop innovative drugs, and promote drug research and development into the era of “smart drugs”. “
Weijie Sun, founder and CEO of DP Technology said, “”As a professional preclinical comprehensive research and development service CRO, Medicilon has rich experience in drug development and high-quality drug preclinical studies’ data on molecular properties and activities, ADME and toxicity. By introducing the AI4S-based drug design platform Hermite® and the molecular pre-training model Uni-Mol for more precise prediction and rapid evaluation, it is expected to help Medicilon speed up the research and development process and provide clients with more efficient, effective and predictable drug evaluation services. “
About DP Technology
As the leader and practitioner of the “AI for Science” scientific research paradigm, DP Technology is committed to using AI and molecular simulation algorithms, combined with advanced computing methods to solve important scientific problems, to create a new generation of micro-scale industrial design and simulation platform for the most basic biomedicine, energy, materials and information science and engineering research of human. DP Technology pioneered the new scientific research paradigm of “multi-scale modeling + machine learning + high-performance computing”, and launched the Bohrium® micro-scale scientific computing cloud platform, Hermite® drug computing design platform, RiDYMO™ Strengthen micro-scale industrial design infrastructure such as dynamics platform and battery material calculation design platform. All these subvert the existing research and development model and creates a new paradigm of “computation-guided experiments and experimental optimization design”. DP Technology is a national high-tech enterprise and a “specialized and new” small and medium-sized enterprise in Beijing. It is headquartered in Beijing and has R&D centers in Shanghai, Shenzhen and other cities in China. The scientific research and technical team is led by academicians of the Chinese Academy of Sciences and has gathered more than 100 outstanding young scientists and engineers in the fields of mathematics, physics, chemistry, biology, materials, and computers. Among them, the company’s doctors and postdoctoral staff accounted for more than 35%. The core members have won the “ACM Gordon Bell Prize”, the highest award in the field of supercomputing in the world in 2020. Their related work was selected as one of the top ten technological advances in China and the top ten technological breakthroughs in the global AI field in 2020.
About Medicilon
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. By the end of 2022, Medicilon has provided new drug R&D services to more than 1,840 clients around the world, and participated in the R&D of 330 new drug projects that have been approved for clinical trials. Medicilon is proud to contribute to human health in the globe.
